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Maintaining protein homeostasis within a cell is 
vital. Recent studies have suggested that therapeutically 
manipulating intracellular protein handling pathways in 
cancer cells perturbs protein homeostasis and results in 
the delivery of a novel apoptotic signal. 
A new paper in Oncotarget by Neznanov et al [1] 
reinforces the potential of proteotoxic stress-targeted 
therapy and in particular demonstrates the ability of 
combinatorial approaches to enhance the antitumor effects 
of the proteasome inhibitor bortezomib by induction of 
protein misfolding using hyperthermia or the antibiotic 
puromycin. In particular, the new results illustrate the 
therapeutic potential of combining non-toxic doses of 
puromycin with bortezomib in a mouse model of multiple 
myeloma. 
There are a number of potential ways of perturbing 
protein homeostasis: firstly by forcing the apoptotic signal 
by disturbing protein quality control with the premature 
degradation of key growth and survival molecules; 
secondly by inhibiting the degradation of proteins 
resulting in a build up of unwanted proteins; or finally by 
interfering with key protein folding pathways resulting in 
the build-up of misfolded proteins. The end result of each 
of these processes is programmed cell death. Crucially, 
malignant cells are more susceptible to killing through 
the manipulation of proteostasis, resulting in a cancer-
selective vulnerability.
The build up of proteins that have failed to fold 
correctly results in the presence of non-functional 
proteins, a tendency toward protein aggregation and 
impaired cellular function and is referred to as proteotoxic 
stress (PS). A cell placed under such stress has two 
possible physiological responses. Initially it will resist 
death whilst attempts at correct protein folding are carried 
out. However, if this fails then an apoptotic signal is 
delivered. Two highly conserved systems are in place 
to combat PS – the unfolded protein response (UPR) 
and the heat shock response (HSR). Both systems act 
as quality control processes ensuring the correct folding 
and 3D conformation for functionally active proteins. 
The UPR senses unfolded native proteins within the 
endoplasmic reticulum (ER) and ensures their correct 
folding, processing, export or degradation. Activation of 
the UPR results in a bias of protein translation towards 
the synthesis of chaperone proteins involved in protein 
folding within the ER, an increase in disposal of misfolded 
proteins via the ubiquitin proteasome pathway, and the 
delivery of a survival signal. If the build-up of misfolded 
protein is irreversible, the cell undergoes apoptosis [2,3]. 
The HSR is activated by the accumulation of non-native 
proteins in the cytosol or nucleus. Once activated there 
is an increase in the synthesis of molecular chaperones 
that both facilitate protein folding and also suppress 
protein aggregation. In addition, the heat shock proteins 
also have a broader anti-apoptotic role mediating both 
the intrinsic mitochondrial-dependent and extrinsic 
death receptor-dependent apoptotic pathways [4,5]. The 
balance, therefore, between the induction of proteotoxic 
stress and the adaptive UPR and HSR is vital for protein 
homeostasis and cell survival (Figure 1).
A number of studies have demonstrated that cancer 
cells have intrinsically high levels of PS. This is a result of 
the accumulation of misfolded proteins caused by cancer 
cells surviving within an unfavourable hypoxic micro-
environment, as well as an increase in protein misfolding Oncotarget 2011; 2:  277 - 280 278 www.impactjournals.com/oncotarget
resulting from aneuploidy and the expression of mutated 
or over-abundant oncogenic proteins, especially in highly 
secretory tumours. The increased level of PS results in a 
dependence of the cancer cell on both the UPR and HSR 
to maintain protein homeostasis and allow survival in 
the stressed malignant state. Studies have demonstrated 
that cancer cells overexpress heat shock protein family 
members [4,5] and have high levels of a number of 
components of the UPR pathway (e.g. XBP1s) [6] which 
aid cell survival and mediate drug resistance.
 
Over recent years a number of investigators have 
attempted to alter the balance between PS, the UPR 
and the HSR to induce cancer cell death. The clinically 
most advanced of these approaches involve the induction 
of PS using either proteasome or heat shock protein 90 
(HSP90) inhibition. The ubiquitin proteasome pathway 
is responsible for the degradation of many key cellular 
signaling proteins. In multiple myeloma, where the use of 
proteasome inhibitors is considered standard of care, both 
in-vitro data and clinical studies have demonstrated that 
inhibition of the catalytic subunit of the 20S proteasome 
Figure 1: Vulnerable proteotoxic stress pathways for exploitation in cancer-selective combinatorial therapies.
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by bortezomib results in a build up of unwanted proteins, 
the induction of cellular stress and apoptosis [7,8]. 
Similar results have been seen both in-vitro and in-vivo in 
solid and hematological malignancies following HSP90 
inhibition [9,10,11]. HSP90 is a crucial chaperone protein, 
ensuring correct folding and activation of its clients, 
which if not correctly folded are targeted for degradation 
by the proteasome. Many of HSP90’s client proteins 
are key tumor growth and survival signaling molecules 
such as EGFR, AKT, BRAF, CRAF, CDK4 and mutant 
p53. HSP90 inhibition results in a decrease in survival 
molecules, thus sensitizing cells to apoptosis, as well as 
preventing correct protein folding leading to increased PS.
In addition to inducing PS, a number of investigators 
have explored approaches aimed at inhibiting the HSR. 
The heat shock protein 70 family (HSP70) is a major 
mediator of the HSR. Heat-shock inducible HSP70 
(HSP72) plays a key role in protecting cells from stress 
by reducing stress-induced protein aggregations and thus 
protecting cells from apoptosis. It also interacts with 
members of the intrinsic and extrinsic apoptotic pathways 
and p53, as well as being a co-chaperone for HSP90. 
The expression of HSP70 family members is tightly 
controlled by the transcription factor, heat shock factor 1 
(HSF1). In response to stress, including HSP90 inhibition, 
HSF1 dissociates from the HSP90/HSP72 complex and 
translocates to the nucleus where it initiates transcription of 
protective stress response chaperones, reducing damaged 
protein aggregations and facilitating degradation by the 
proteasome. The constitutively expressed heat shock 
cognate 70 (HSC70), another HSP70 family member, also 
plays a significant anti-apoptotic role. Our own studies 
have shown that silencing HSC70 or HSP72 alone has 
no effect on tumor cell death, whereas simultaneously 
reducing the expression of both of these isoforms induces 
degradation of HSP90 clients, G1 arrest and apoptosis 
[12,13]. Others have shown similar results with HSF1 
silencing [14,15].
A number of groups have explored a combination 
of the above approaches – targeting PS and HSR 
simultaneously. Proteasome or HSP90 inhibition results 
in activation of the HSR via HSF1 driving upregulation of 
HSP70 family members [3,10,16]. Using siRNA we have 
shown increased susceptibility to HSP90 inhibitors when 
HSP72 and HSC70 are targeted simultaneously [12,16]. 
Therefore, combinations involving either the proteasome 
or HSP90 inhibition with HSP70 targeting offers an 
attractive way to potentiate single agent therapeutic 
activity.
Neznanov  et al present a further approach to 
manipulating the balance between PS and HSR [1]. 
Rather than inhibiting the HSR, they dramatically increase 
PS by both inducing protein misfolding and inhibiting 
protein degradation via the proteasome, so-called 
‘enhanced proteotoxic stress’. They demonstrate that the 
increased level of misfolded proteins, induced by either 
hyperthermia or puromycin (which works by causing 
premature termination of translation and accumulation of 
aborted and incorrectly folded products) in combination 
with bortezomib, could not be matched by the cancer 
cell’s ability to synthesize chaperones as part of the HSR 
and thus cell death ensued. The studies indicate that the 
enhanced proteotoxic death is, at least in part, mediated 
through p53. This raises questions as to the effect of p53 
status in tumor versus healthy cells on the response to 
combinatorial treatments proposed. Importantly, however, 
the synergistic anticancer effect was seen both in-vitro 
and an in-vivo mouse model of multiple myeloma and 
thus provides a rationale for attempting such an approach 
or other PS combinations in the clinical arena.
A wealth of data now supports various tactics to 
modulate protein homeostasis as an approach to cancer-
selective therapy. The stressed state of malignant cells 
leaves them vulnerable to therapeutic strategies that 
target molecular determinants of the UPR or the HSR – 
or a combination of the two – as orthogonal approaches 
to exacerbate enhanced PS. Indeed stress phenotypes, 
including PS, can now be included among the extended 
hallmarks of cancer – in addition to the Hanahan and 
Weinberg traits [17]. Furthermore, proteotoxic stress 
targets can be considered as part of a broader conceptual 
framework in which non-oncogene targets as well as 
oncogene targets can be attacked in tumour-selective 
therapy [17].
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